

Safety of Recombinant Zoster Vaccine: a Retrospective Study of 622 Rheumatology Patients

Tiphaine Lenfant, Yuxuan Jin, Elizabeth Kirchner, Rula Hajj-Ali, Leonard H. Calabrese, Cassandra Calabrese Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic Foundation





COI DISCLOSURE INFORMATION Tiphaine Lenfant, MD



I have no financial relationships to disclose.



Rationale

Recombinant Zoster Vaccine (RZV) and Immune Mediated Inflammatory Diseases (IMIDs)

Rationale

- Higher risk of herpes zoster (HZ) in:
 - IMID patients (RA, SLE, etc.)
 - Immunosuppressive (IS) medications
- Recombinant Zoster Vaccine (RZV)
 - Novel adjuvant AS01B: highly immunogenic
 - Theoretical risk of IMID flares
- Are rheumatic diseases patients at higher risk of flare after RZV?

Yun H et al. Arthritis Rheumatol. 2016;68(9):2328-37. Lal H et al. N Engl J Med. 2015;372(22):2087-96. Lecrenier N et al. Expert Rev Vaccines. 2018;17(7):619-34. Convergence



Patients and Methods

Patients and Methods



Study design

- Retrospective
- Single center
- Data collected from EMR


Patients

- Rheumatic disease patients
 - IMIDs and non IMIDs
- Vaccinated by ≥ 1 dose of RZV
- February 2018 \rightarrow May 2020

Outcomes

1) Flares of the underlying IMID

- Collected via chart review, office notes, new or higher prednisone prescription, treatment changes
- In the 12-week period after each RZV
- 2) Adverse events and HZ outbreaks







Results

n=622 patients, 359 IMIDs

- Median age 67, 67% female
- 77% received 2 RZV doses
- Median follow-up 36 weeks
- 359 IMID patients
 - RA n=88
 - Vasculitis n=50
 - PMR n=29
 - Gout n=28
 - SLE n=24
 - PsA n=20




Figure 1: Panel of treatments received by IMID patients at the time of RZV



Results (2): IMID flares

- Among 359 IMID patients,
- 59 flared after RZV (16%)
 - 34 after 1st dose (median time to flare: 31 days)
 - 17 after 2nd dose (45 days)
 - 8 after both doses (17 & 40 days)



Results (3): Flares n=59 IMID flares after RZV

- RA patients had the highest
- flare rate (24%)
- Flares occurred in a temporal relation to a treatment change in 18 cases (31%)
- Management of flares:
 - Glucocorticoids (GC) (n=27, 45%)
 - Change in IS therapy (n=15, 25%)



IMID subgroups	Total IMID	On GC	≥1 Flare*
	n=359 (100%)	n=125 (35%)	n=59 (16%)
RA	88 (25%)	37 (42%)	21 (24%)
Vasculitis	50 (14%)	23 (46%)	5 (10%)
PMR	29 (8%)	21 (72%)	5 (17%)
Gout	28 (8%)	3 (11%)	5 (18%)
SLE	24 (7%)	10 (42%)	4 (17%)
PsA	20 (6%)	6 (30%)	2 (10%)
Inflammatory arthritis	19 (5%)	5 (26%)	3 (16%)
Sjögren	18 (5%)	0 (0%)	2 (11%)
SpA	17 (5%)	2 (12%)	2 (12%)
CPPD	14 (4%)	2 (14%)	3 (21%)
Myositis	9 (3%)	3 (33%)	2 (22%)
Scleroderma	9 (3%)	1 (11%)	0 (0%)
IBD related arthritis	8 (2%)	1 (13%)	1 (13%)
Other	26 (7%)	11 (42%)	4 (15%)

Table 1: Proportion of IMID patients, GC regimen and flares

Results (4) Risk factors for IMID flares

- Multivariate model of logistic regression:
- Controlling for Jakinhibition and RA
- Only GC use at the time of vaccine remained significantly associated with IMID flares
- OR = 2.31 [1.3-4.1] p=0.004



	No flare (n=300)	Flare (n=59)	Univ analysis p value	for significant Adjusted OR [IC95%]	-
Median age (years)	67	67	0.962		
Gender (female)	66%	63%	0.592		
Ethnicity (white)	84%	86%	0.445		
RA(vs others)	n=67 22%	n=21 36%	0.030	1.57 [0.8-2.98]	0.173
Glucocorticoids	31%	53%	0.002	2.31 [1.3-4.1]	0.004
Jak-inhibitors	4%	10%	0.032	2.09 [0.64-6.34]	0.203
Hydroxychloroquine	21%	25%	0.416		
Methotrexate	22%	25%	0.565		
TNF inhibitors	14%	17%	0.509		
Other biologic	12%	15%	0.539		
Other immunosuppressant	14%	19%	0.358		

Table 2: Risk factors of IMID flares in a cohort of 359 IMID patients vaccinated with RZV

No significant association with laboratory findings (CRP, ESR, ANA, ENA, RF, CCP)

Results (5): Time-to-flare Multivariate Cox-model (n=359 IMID patients)






Figure 2A. Survival analysis of the time to flare in the 12-week time period following the first dose of RZV in 359 IMID patients (multivariate Cox-model

Results (5): Time-to-flare Multivariate Cox-model (n=263 that received 2 RZV doses)






Figure 2B. Survival analysis of the time to flare in the 12-week time period following the second dose of RZV in 263 IMID patients having received both doses (multivariate Cox-model).

Key take away points

- Use of RZV appears safe in IMID patients
- Mild flares were not uncommon in the first 12 weeks after RZV
- GC use at the time of RZV administration was associated with a significantly higher rate of flares in IMID patients
- Having flared after the first dose was associated with a higher risk of flare after the second dose.



Iew

Convergence

1. Rationale

IMID patients / IMID treatments = higher risk of zoster Recombinant Zoster Vaccine: available, high efficacy, new adjuvant

Adjuvant -> Theoretical risk of flares after vaccine



67% female Median age 67 yo


77% received 2 doses

8.7% adverse events

2.Study

Retrospective single-center study (Rheumatology, CCF, USA) Inclusion: ≥1 RZV dose between Feb. 2018 and May 2020 Data extracted from Electronic Medical Records

Flares in the 12-week period after each dose? Risk factors? ≻ Adverse events? Zoster outbreak? ≽



3. Results



n=622 rheumatology patients n=359 IMID patients

Which IMID/treatment? Flared after RZV?


Description	n

Flares: n=59

A change in IS treatment was needed in 25%

IMID subgroups	Total from IMID (n=359)	On GC n=125 (35%)	≥1 Flare n=59 (16%)
RA	88 (25%)	37 (42%)	21 (24%)
Vasculitis	50 (14%)	23 (46%)	5 (10%)
PMR	29 (8%)	21 (72%)	5 (17%)
Gout	28 (8%)	3 (11%)	5 (18%)
SLE	24 (7%)	10 (42%)	4 (17%)

-0-00 -000 -0-00	Risk factor	No flare (n=300)	Flare (n=59)	Univariate p-value	Multivariate OR [IC95]	p-value
	RA	67 (22%)	21 (36%)	0.030	1.57 [0.8-3]	0.173
	GC	31%	53%	0.002	2.31 [1.3-4]	0.004
Logistic regression	Jak-i	4%	10%	0.032	2.09 [0.6-6]	0.203



Key messages



- ✓ RZV appears safe in IMID patients
- ✓ GC at time of vaccine = higher risk of flare
- ✓ Patient + Provider discussion
- ✓ Informed consent
- Benefits / Risks Balance
- GC









American College of Rheumatology 2200 Lake Boulevard NE Atlanta, GA 30319 Phone: 404-633-3777, ext. 815